Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion

Diagnostic Cytopathology

Volumn 34, Issue 1, 2006, Pages 6-10

  Ueda, Junko ^a   Iwata, Takako ^a   Ono, Midori ^a   Takahashi, Mutsuo ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenocarcinoma cells; Differential diagnosis; Effusion; Immunocytochemistry; Reactive mesothelial cells

Indexed keywords

ALCOHOL; CARCINOEMBRYONIC ANTIBODY; EPITHELIAL MEMBRANE ANTIBODY; FORMALDEHYDE; MONOCLONAL ANTIBODY BER EP4; MONOCLONAL ANTIBODY CA 125; MONOCLONAL ANTIBODY CA 19-9; MONOCLONAL ANTIBODY HBME 1; MONOCLONAL ANTIBODY MOC 31; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ANTIBODY SCREENING; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; EFFUSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; MESOTHELIUM CELL; PRIORITY JOURNAL; REACTIVE MESOTHELIUM CELL; SENSITIVITY AND SPECIFICITY; SMEAR; TISSUE FIXATION;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ASCITIC FLUID; CYTODIAGNOSIS; DIAGNOSIS, DIFFERENTIAL; EPITHELIAL CELLS; HISTOCYTOLOGICAL PREPARATION TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; PLEURAL EFFUSION; SENSITIVITY AND SPECIFICITY; TISSUE EMBEDDING; TUMOR MARKERS, BIOLOGICAL;

EID: 30344471126     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/dc.20391     Document Type: Article

References (19)

1. Riera JR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma:a reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 1997;21:1409-1419.
2. Ordóñez NG. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update. Am J Clin Pathol 1999;112:75-89.
3. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000;36:341-347.
4. Frisman DM, McCarthy WF, Schleiff P, et al. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Mod Pathol 1993;6:179-184.
5. Lee JS, Nam JH, Lee MC, Park CS, Juhng SW. Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in serous effusions. Acta Cytol 1996;40:631-636.
6. Delahaye M, van der Ham F, van der Kwast TH. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Diagn Cytopathol 1997;17:115-120.
7. Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer 1998;84:101-108.
8. Morgan RL, De Young BR, McGaughy VR, Niemann TH. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells. Cancer 1999;87:390-394.
9. Gill SA, Meier PA, Kendall BS. Use of desmin immunohistochemistry to distinguish between mesothelial cells and carcinoma in serous fluid cell block preparations. Acta Cytol 2000;44:976-980.
10. Fetsch PA, Simsir A, Brosky K, Abati A. Comparison of three commonly used cytologic preparations in effusion immunocytochemistry. Diagn Cytopathol 2002;26:61-66.
11. Mulvany N. Cytohistologic correlation in malignant peritoneal washings. Analysis of 75 malignant fluids. Acta Cytol 1996;40:1231-1239.
12. Fetsch PA, Abati A. Immunocytochemistry in effusion cytology: a contemporary review. Cancer 2001;93:293-308.
13. Mensch LS, Weller L, Simmons-Arnold L, et al. GLUT1 antibody staining in thin-layer specimens of benign and malignant body cavity effusions. Acta Cytol 2002;46:813-818.
14. Lozano MD, Panizo A, Toledo GR, Sola JJ, Pardo-Mindan J. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Cancer 2001;93:68-72.
15. Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers. Virchows Arch 1999;435:43-49.
16. Kitamura K, Mukai K, Inayama Y, et al. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining. Cancer 2000;90:55-60.
17. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology 2000;11:8-17.
18. Gong Y, Sun X, Michael CW, et al. Immunocytochemistry of serous effusion specimens: a comparison of ThinPrep vs. cell block. Diagn Cytopathol 2003;28:1-5.
19. Latza U, Niedobitek G, Schwarting R, Nekarda H, Stein H. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelia. J Clin Pathol 1990;43:213-219.